How do the results of the RADIANT trials impact on the management of NET patients? A systematic review of published studies

Sara Pusceddu, Filippo De Braud, Giuseppe Lo Russo, Laura Concas, Daniela Femia, Claudio Vernieri, Alice Indini, Barbara Formisano, Roberto Buzzoni

Research output: Contribution to journalArticle

Abstract

In the last five years, everolimus has demonstrated efficacy in the treatment of neuroendocrine tumors (NETs) of different origins; its efficacy and safety were explored in the RADIANT trials, the last of which (RADIANT-4) has been recently published (December 2015). Overall, evidence collected from the RADIANT studies holds promise to change clinical practice for the treatment of NETs. In this paper, we comment on the role of everolimus within the therapeutic algorithm for NETs treatment, based on the systematic analysis of the RADIANT trials and our experience.

Original languageEnglish
Pages (from-to)44841-44847
Number of pages7
JournalOncotarget
Volume7
Issue number28
DOIs
Publication statusPublished - 2016

Keywords

  • Everolimus
  • Neuroendocrine tumors

ASJC Scopus subject areas

  • Oncology

Fingerprint Dive into the research topics of 'How do the results of the RADIANT trials impact on the management of NET patients? A systematic review of published studies'. Together they form a unique fingerprint.

  • Cite this